InGell Labs BV (IGL – Groningen, The Netherlands) is an SME which develops injectable drug-depots for slow release of a broad range of therapeutic actives, all based on its patent-protected InGell®-platforms, and with rapid access to scale-up for cGMP processing. Applications are done with major Pharma companies in Diabetes, Pain management, OA, and CNS. Public-Private partnerships exist in orthopaedic, veterinary and oncology applications with UU-UMCU-UMCG-LUMC and UTwente.
The company has developed two different polymer-based drug delivery platforms: InGell®-Gamma (hydrogel-depots) and InGell®-LQP (pure polymer depots). The platforms offer injectable drug delivery depots, which are formulated and delivered as liquids through thin needles (up to 31G).
Company Details
- Founded
- -
- Address
- Groningen, Groningen
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- ingell.nl
- HQ
- Groningen, Groningen
Ingell Labs Bv Questions
Ingell Labs Bv's website is ingell.nl
Ingell Labs Bv's LinkedIn profile is https://nl.linkedin.com/company/ingell-labs-bv
Ingell Labs Bv's industry is
Pharmaceutical Manufacturing
Ingell Labs Bv's top competitors are
Regenity Biosciences (Formerly Polyganics),
Synano,
Chiptech Twente,
Axon Medchem,
Pharmacytics,
Liposoma,
Seranovo,
Novosere,
Incircular,
Profluid.
Ingell Labs Bv's categories are Pharmaceutical Manufacturing
Ingell Labs Bv's founding year is 2010
